Vimarsana
Biggest News Aggregation in the World

Tarsu Form News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tarsu Form. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tarsu Form Today - Breaking & Trending Today

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon - Vimarsana News

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

IRVINE, Calif., April 23, 2024 -- Tarsus Pharmaceuticals, Inc. , whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,...

Tarsus Announces Pricing of $100.0 Million Public Offering - Vimarsana News

Tarsus Announces Pricing of $100.0 Million Public Offering

IRVINE, Calif., March 01, 2024 -- Tarsus Pharmaceuticals, Inc. , whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,...

Tarsus Announces Proposed $100.0 Million Public Offering - Vimarsana News

Tarsus Announces Proposed $100.0 Million Public Offering

IRVINE, Calif., Feb. 29, 2024 -- Tarsus Pharmaceuticals, Inc. , whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,...

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept "Tick-Kill" Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease -February 22, 2024 at 08:03 am EST - Vimarsana News

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept "Tick-Kill" Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease -February 22, 2024 at 08:03 am EST

TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 -- Tarsus Pharmaceuticals,...

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock - Vimarsana News

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., Aug. 01, 2023 -- Tarsus Pharmaceuticals, Inc. , whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,...